Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.

Browne, Sarah K et al.·JHEP reports : innovation in hepatology·2025·
RPEP-102362025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
Published In:
JHEP reports : innovation in hepatology, 7(11), 101483 (2025)
Database ID:
RPEP-10236

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10236·https://rethinkpeptides.com/research/RPEP-10236

APA

Browne, Sarah K; Suschak, John J; Tomah, Shaheen; Gutierrez, Julio A; Yang, Jay; Georges, Bertrand; Roberts, M Scot; Harris, M Scott. (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.. JHEP reports : innovation in hepatology, 7(11), 101483. https://doi.org/10.1016/j.jhepr.2025.101483

MLA

Browne, Sarah K, et al. "Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.." JHEP reports : innovation in hepatology, 2025. https://doi.org/10.1016/j.jhepr.2025.101483

RethinkPeptides

RethinkPeptides Research Database. "Safety and efficacy of 24 weeks of pemvidutide in metabolic ..." RPEP-10236. Retrieved from https://rethinkpeptides.com/research/browne-2025-safety-and-efficacy-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.